Bausch Health Companies BHC Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Bausch + Lomb | $5.21B+7.8% | $5.1B+6.5% | $4.98B+6.2% | $4.89B+8.8% | $4.83B+11.9% | |
| Diversified | $917M-3.8% | $937M-1.4% | $910M-7.2% | $921M-5.1% | $953M+0.5% | |
| International | $1.16B+4.2% | $1.13B+1.9% | $1.11B-1.5% | $1.11B+0.4% | $1.11B+1.7% | |
| Salix | $2.68B+12.6% | $2.58B+10.5% | $2.52B+10.4% | $2.45B+8.5% | $2.38B+5.5% | |
| Solta Medical | $576M+23.9% | $518M+17.7% | $519M+28.1% | $491M+30.6% | $465M+28.5% | |
| Operating Income (Loss) by Business | ||||||
| Bausch + Lomb | $1.22B+16.8% | $1.13B+1.5% | $1.04B-3.9% | $1.02B-2.0% | $1.05B+3.5% | |
| Diversified | $612M-4.2% | $627M+0.2% | $605M-5.2% | $612M-1.4% | $639M+7.8% | |
| International | $337M-9.9% | $334M-11.2% | $351M-6.9% | $366M+0.8% | $374M+8.4% | |
| Salix | $2.02B+23.0% | $1.93B+20.2% | $1.86B+18.9% | $1.72B+10.8% | $1.64B+5.2% | |
| Solta Medical | $254M+12.4% | $232M+8.9% | $250M+33.7% | $233M+39.5% | $226M+37.0% | |
| SG&A by Business | ||||||
| Bausch + Lomb | $1.77B+2.4% | $1.78B+5.4% | $1.78B+11.1% | $1.77B+15.5% | $1.73B+18.9% | |
| Diversified | $167M+0.6% | $169M0.0% | $164M-9.6% | $163M-13.8% | $166M-12.9% | |
| International | $247M+16.0% | $236M+10.3% | $222M+3.1% | $219M+3.1% | $213M+3.0% | |
| Salix | $396M-15.2% | $402M-12.2% | $409M-10.1% | $477M+15.8% | $467M+12.8% | |
| Solta Medical | $138M+22.1% | $131M+19.1% | $124M+25.3% | $119M+25.3% | $113M+24.2% | |
| R&D by Business | ||||||
| Bausch + Lomb | $161M+33.1% | $144M+19.0% | $138M+17.4% | $126M+5.9% | $121M+1.3% | |
| Diversified | $14M0.0% | $14M-6.7% | $14M-9.7% | $14M-17.6% | $14M-20.0% | |
| International | $27M+8.0% | $27M+12.5% | $26M+14.3% | $24M+2.1% | $25M+12.4% | |
| Salix | $81M-9.0% | $79M-20.2% | $82M-19.6% | $80M-26.6% | $89M-15.2% | |
| Solta Medical | $29M+52.6% | $26M+44.4% | $26M+52.9% | $22M+29.4% | $19M0.0% | |
| Additions by Business | ||||||
| Bausch + Lomb | $72.75M— | $97M— | $99.75M— | —— | —— | |
| Diversified | $0— | $0— | $0— | —— | —— | |
| International | $0— | $0— | $0— | —— | —— | |
| Salix | $0— | $0— | $0— | —— | —— | |
| Solta Medical | $16.5M— | $22M— | $16.5M— | —— | —— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Bausch + Lomb | -$83M-1,022% | -$148M-283% | -$59M-5.4% | -$100M-500% | $9M+80.0% | |
| International | -$56M— | -$110M— | -$46M— | —— | —— | |
| Salix | $0— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Bausch + Lomb | $21.78B+2.9% | $21.61B+2.2% | $21.37B+0.8% | $21.29B+0.7% | $21.17B+0.1% | |
| Diversified | $6.61B-5.2% | $6.78B-2.9% | $6.96B+0.1% | $6.96B-1.4% | $6.98B-7.5% | |
| International | $3.56B+7.9% | $3.51B+5.4% | $3.4B+0.2% | $3.36B-0.1% | $3.3B-2.3% | |
| Salix | $11.21B-11.3% | $12.64B0.0% | $12.64B0.0% | $12.64B0.0% | $12.64B0.0% | |
| Solta Medical | $504M+9.6% | $482M+4.8% | $460M0.0% | $460M0.0% | $460M0.0% | |
| Goodwill, impairment loss by Business | ||||||
| Bausch + Lomb | $0— | $0— | —— | —— | —— | |
| Diversified | $108.75M— | $145M— | —— | —— | —— | |
| International | $0— | $0— | —— | —— | —— | |
| Salix | $1.43B— | $0— | —— | —— | —— | |
| Solta Medical | $0— | $0— | —— | —— | —— | |
| Revenue by Product | ||||||
| Other revenues | $102M-11.3% | $110M+2.8% | $113M+10.8% | $117M+18.2% | $115M+19.8% | |
| Price Appreciation Credit | $18M-10.0% | $18M0.0% | $21M+90.9% | $20M+81.8% | $20M+81.8% | |
| Product sales | $10.43B+8.5% | $10.16B+6.7% | $9.92B+5.8% | $9.74B+7.0% | $9.62B+8.4% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $63M+6.8% | $64M+20.8% | $65M+38.3% | $64M+45.5% | $59M+40.5% | |
| Product sales | $2.99B+7.3% | $2.95B+8.1% | $2.88B+6.0% | $2.82B+6.8% | $2.78B+8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch Health Companies break its business down?
- Bausch Health Companies (BHC) reports revenue by business across 5 parts — Bausch + Lomb, Diversified, International, Salix and Solta Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch Health Companies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch Health Companies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.